Education
About Us
Working with TipRanks
Follow Us
Harvard Bioscience (HBIO)
:HBIO
Earnings Data
Report Date
Mar 05, 2026After Close (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
0.04Last Year’s EPS
0.06Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong operational improvements, a significant increase in backlog and order growth, successful product launches, and positive cash flow management. However, these positives were somewhat offset by year-over-year revenue decline, challenges in the China market, and uncertainty due to the U.S. government shutdown affecting NIH funding. Overall, the company's efforts to enhance operational efficiency and increase product demand reflect a positive outlook despite some ongoing challenges.Company Guidance
Revenue and Margin Performance
Revenue for Q3 2025 was $20.6 million, at the high end of the guidance range of $19-21 million, with a slight sequential increase in a typically weak quarter. Gross margin improved to 58.4%, exceeding the guidance range of 56-58%.
Operational Improvements
Adjusted EBITDA increased to $2 million from $1.3 million in Q3 2024. Operating expenses declined by $1.4 million due to efficiency measures, leading to improved adjusted operating income.
Product and Market Advancements
Successful launch of the Incub8 Multiwell System and expanded distribution agreement with Fisher Scientific. Increased demand for the SoHo Telemetry and Biochrom amino acid analyzer.
Strong Backlog and Order Growth
The backlog reached its highest level in nearly two years, with quarterly order growth for the first time in over 12 months and a strong uptick in Europe.
Positive Cash Flow and Debt Reduction
Generated $6.8 million in operating cash flow year-to-date, with net debt reduced by over $6 million from year-end 2024 to $27.5 million.
HBIO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
HBIO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 06, 2025 | $0.59 | $0.54 | -8.47% |
Aug 11, 2025 | $0.53 | $0.48 | -9.43% |
May 12, 2025 | $0.32 | $0.35 | +9.37% |
Mar 12, 2025 | $0.76 | $0.68 | -10.53% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Harvard Bioscience (HBIO) report earnings?
Harvard Bioscience (HBIO) is schdueled to report earning on Mar 05, 2026, After Close (Confirmed).
What is Harvard Bioscience (HBIO) earnings time?
Harvard Bioscience (HBIO) earnings time is at Mar 05, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is HBIO EPS forecast?
HBIO EPS forecast for the fiscal quarter 2025 (Q4) is 0.04.